Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
8 studies found for:    lirilumab
Show Display Options
Rank Status Study
1 Recruiting An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: 5-azacytidine;   Drug: Lirilumab;   Behavioral: Phone Call
2 Recruiting Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Lymphocytic Leukemia
Interventions: Drug: Lirilumab;   Drug: Rituximab
3 Active, not recruiting A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
4 Recruiting Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Condition: Leukemia
Interventions: Drug: Lirilumab;   Drug: Nivolumab;   Drug: Azacitidine
5 Recruiting A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Condition: CANCER,NOS
Interventions: Drug: Lirilumab;   Drug: Nivolumab;   Drug: Ipilimumab
6 Completed Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
Condition: Acute Myeloid Leukemia
Interventions: Drug: IPH2102 at 0.1 mg/kg;   Drug: IPH2102 at 1 mg/kg;   Drug: Placebo (normal saline solution)
7 Completed Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Condition: CANCER, NOS
Interventions: Drug: Lirilumab;   Drug: Ipilimumab
8 Recruiting An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab;   Biological: Daratumumab;   Drug: Pomalidomide;   Drug: Dexamethasone

Study has passed its completion date and status has not been verified in more than two years.